Please login to the form below

Not currently logged in
Email:
Password:

EMA’s Paediatric Committee elects new leaders

Dirk Mentzer and Henk van den Berg elected as chair and vice-chair

Dirk Mentzer The European Medicines Agency's (EMA) Paediatric Committee (PDCO) last week elected Dirk Mentzer and Henk van den Berg chair and vice-chair, respectively, at its September meeting. Both have been elected for a three-year term. 

A paediatrician by training, Dr Mentzer is currently head of the pharmacovigilance unit at the Paul-Ehrlich Institut in Frankfurt, Germany.  He is an expert in paediatric specialist training, including neonatology and paediatric accident and emergency admissions. 

Dr Van den Berg is a consultant in paediatric haematology / oncology at the Medicines Evaluation Board in Utrecht, the Netherlands.  His areas of expertise include paediatric haematology, clinical pharmacology and medical education. 

On their election, Mentzer and van den Berg thanked outgoing chair Daniel Brasseur, who has left the PDCO to become a member of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Both Mentzer and van den Berg have been members of the PDCO since it was established in 2007. The committee's main role is to assess the content of paediatric investigation plans (PIPS). It meets for three days each month at the EMA in London.

19th September 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics